(Q45879854)

17 December 2017

title

Ignoring the nonsense: a phase II trial in cystic fibrosis (English)

1 reference

17 December 2017

main subject

phase II clinical trial

0 references

0 references

1

1 reference

17 December 2017

author name string

Deborah R Gill

series ordinal

2

1 reference

17 December 2017

language of work or name

English

0 references

publication date

20 August 2008

1 reference

17 December 2017

published in

The Lancet

1 reference

17 December 2017

volume

372

1 reference

17 December 2017

issue

9640

1 reference

17 December 2017

page(s)

691-692

1 reference

17 December 2017

When the message goes awry: disease-producing mutations that influence mRNA content and performance.

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961169-1

7 January 2021

Nonsense-mediated decay approaches the clinic

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961169-1

7 January 2021

Evidence for airway surface dehydration as the initiating event in CF airway disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961169-1

7 January 2021

Population variation of common cystic fibrosis mutations. The Cystic Fibrosis Genetic Analysis Consortium

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961169-1

7 January 2021

Efficiency of gene transfer for restoration of normal airway epithelial function in cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961169-1

7 January 2021

Aminoglycoside antibiotics restore CFTR function by overcoming premature stop mutations

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961169-1

7 January 2021

Evidence that systemic gentamicin suppresses premature stop mutations in patients with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961169-1

7 January 2021

Gentamicin-Induced Correction of CFTR Function in Patients with Cystic Fibrosis andCFTRStop Mutations

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961169-1

7 January 2021

Aminoglycosides: nephrotoxicity

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961169-1

7 January 2021

A biochemical basis for the inherited susceptibility to aminoglycoside ototoxicity

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961169-1

7 January 2021

PTC124 targets genetic disorders caused by nonsense mutations

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961169-1

7 January 2021

Safety, tolerability, and pharmacokinetics of PTC124, a nonaminoglycoside nonsense mutation suppressor, following single- and multiple-dose administration to healthy male and female adult volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961169-1

7 January 2021

Effectiveness of PTC124 treatment of cystic fibrosis caused by nonsense mutations: a prospective phase II trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961169-1

7 January 2021

10.1016/S0140-6736(08)61169-1

Identifiers

DOI

1 reference

17 December 2017

1 reference

17 December 2017